Definition
Biobucks is industry slang for the headline value of a biotech licensing or partnership deal, or more narrowly for the milestone payments that make up most of it. A deal announced as "worth up to $2 billion" usually means a much smaller payment at signing, plus a long list of payments that are made only if the drug passes specific stages. If the drug fails, the remaining payments are never made. STAT has compared them to lottery tickets.
What Is Inside a Headline Number
| Component | When it is paid | How certain |
|---|---|---|
| Upfront payment | At signing | Certain |
| Research funding or fees | During the collaboration | Likely while the work continues |
| Near-term milestones | On early events, such as choosing a candidate | Contingent, but closer |
| Development and regulatory milestones | On trial starts, trial results and approvals | Contingent on the drug succeeding |
| Commercial or sales milestones | When sales pass set levels | Contingent on an approved drug selling well |
| Royalties | As a share of sales | Usually not counted in the headline at all |
How Much Actually Gets Paid
- A STAT analysis in 2016, using EvaluatePharma data on nearly 700 licensing deals over four years, found that about 14% of announced value was paid at signing on average. The share was about 18% in 2014 and about 11% in the first nine months of 2016.
- A 2025 report from SRS Acquiom on 342 life-science acquisitions with milestone clauses, signed from 2008 to 2025, found that about $9 billion of $95.1 billion in potential milestone payments had been paid, or about 9.5%, as reported by BioSpace. For the biopharma deals, 19% of the milestones that had come due were paid.
The two studies cover different deal types, licensing in one and acquisitions in the other, so the percentages are not directly comparable. Both point the same way.
Three 2026 Examples
| Deal | Announced | Paid upfront or near-term | Headline | Share of headline |
|---|---|---|---|---|
| Eli Lilly and Insilico Medicine | March 29, 2026 | $115M upfront | About $2.75B total | About 4% |
| AstraZeneca and insitro | October 2026 | $40M upfront | $40M plus up to about $1.46B in milestones | Under 3% |
| SK Biopharmaceuticals and Insilico Medicine | June 22, 2026 | Up to $18M in upfront and near-term milestones | Above $2.5B total | Under 1% |
The shares are our arithmetic on the announced figures. Fierce Biotech used the word directly in July 2026, calling Takeda's agreement with Insilico a "$600M biobucks" collaboration. In that deal about $60 million is initiation fees, near-term payments and milestones, and the rest depends on later success. The full list of 2026 deals is in the AI pharma deal tracker.
How to Read an "Up To $X" Announcement
- Find the upfront payment. It is the only amount that is certain. If the release gives only a total, as Takeda and Iambic did in February 2026, treat the certain amount as unknown.
- Check whether "upfront" is blended. Phrases such as "upfront and near-term milestones" mix certain money with conditional money. The true upfront is smaller than the figure given.
- See what the milestones depend on. Sales milestones need an approved drug that sells well. The SRS Acquiom report found that in about a quarter of deals, payments tied to at least $1 billion in sales made up nearly half of the milestone total.
- Count the programmes. A total that covers several targets assumes every one of them succeeds.
- Look at the stage. Milestones on preclinical programmes are years away and most programmes do not reach approval.
- Note whether royalties are included. They are usually on top of the headline.
Why Deals Are Built This Way
Milestones let the two sides share risk. The larger company commits little cash until the science proves out. The smaller company gets a large number to announce and keeps a stake in success. Neither side is hiding anything, since the structure is normally stated in the release. The problem is only when the headline is read as cash.
Where It Does Not Apply
Not every "up to" figure is biobucks. The "up to $1 billion" in the Nvidia and Lilly lab announcement is a ceiling on joint spending over five years, with no milestones. Venture funding rounds, such as the $2.1 billion raised by Isomorphic Labs, are cash invested for equity and are not contingent in this way.
Sources
STAT, November 2016 for the definition and the licensing figures. BioSpace, October 2025 for the SRS Acquiom report. Wikipedia for general usage. Deal figures are from the company releases linked on the deal tracker page, and Fierce Biotech for the Takeda headline. Nothing here is investment advice.